Mumbai, Aug. 20 -- The company said the product is bioequivalent and therapeutically equivalent to Flonase Nasal Spray, 0.05 mg/spray, the reference listed drug of Haleon US Holdings. Glenmark Pharmaceuticals Inc., USA, will distribute the product in the U.S.
According to IQVIA sales data for the 12-month period ending June 2026, the Flonase Nasal Spray market recorded annual sales of approximately $295.2 million.
Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. The company reported a 6,381.9% increase in consolidated net profit to Rs 301.41 crore on a 16.8% increase ...